

D-Amino Acid-Containing Lipopeptides Derived from the Lead Peptide BP100 with Activity against Plant Pathogens

Àngel Oliveras ¹, Luís Moll ², Gerard Riesco-Llach ¹, Arnau Tolosa-Canudas ¹, Sergio Gil-Caballero ³, Esther Badosa ², Anna Bonaterra ², Emilio Montesinos ², Marta Planas ^{1,*} and Lidia Feliu ^{1,*}

Table of contents:

1. Biological activity of lipopeptides.....	2
2. Synthesis of lipopeptides	5
3. HPLC of crude and purified lipopeptides, ESI-MS and HRMS of purified lipopeptides	11
4. NMR experiments of lipopeptides BP389 and BP475	81

1. Biological activity of lipopeptides

Table S1. Antimicrobial activity (MIC) of lipopeptides

Peptide ^a	MIC (μM)							
	<i>Ea</i> ^b	<i>Pss</i> ^b	<i>Xap</i> ^b	<i>Xf</i> ^b	<i>Psa</i> ^b	<i>Xav</i> ^b	<i>Pe</i> ^b	<i>Fo</i> ^b
BP367	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	12.5-25	1.6-3.1
BP472	3.1-6.2	3.1-6.2	1.6-3.1	1.6-3.1	1.6-3.1	1.6-3.1	>25	3.1-6.2
BP371	3.1-6.2	3.1- 6.2	3.1- 6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	0.8-1.6
BP484	6.2-12.5	3.1-6.2	3.1-6.2	1.6-3.1	3.1-6.2	6.2-12.5	6.2-12.5	1.6-3.1
BP374	3.1-6.2	6.2-12.5	6.2-12.5	3.1-6.2	3.1-6.2	6.2-12.5	>25	0.8-1.6
BP494	6.2-12.5	3.1-6.2	6.2-12.5	12.5-25	3.1-6.2	6.2-12.5	0.8-1.6	3.1-6.2
BP378	3.1-6.2	6.2-12.5	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	0.8-1.6
BP495	3.1-6.2	3.1-6.2	3.1-6.2	6.2-12.5	1.6-3.1	6.2-12.5	0.8-1.6	1.6-3.1
BP379	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	6.2-12.5	3.1-6.2
BP485	6.2-12.5	3.1-6.2	1.6-3.1	1.6-3.1	3.1-6.2	1.6-3.1	3.1-6.2	1.6-3.1
BP381	3.1-6.2	3.1-6.2	3.1-6.2	1.6-3.1	3.1-6.2	1.6-3.1	1.6-3.1	0.8-1.6
BP486	6.2-12.5	12.5-25	3.1-6.2	3.1-6.2	6.2-12.5	6.2-12.5	6.2-12.5	0.8-1.6
BP384	3.1-6.2	6.2-12.5	3.1-6.2	1.6-3.1	6.2-12.5	1.6-3.1	12.5-25	1.6-3.1
BP498	6.2-12.5	6.2-12.5	1.6-3.1	3.1-6.2	6.2-12.5	1.6-3.1	1.6-3.1	0.8-1.6
BP385	6.2-12.5	6.2-12.5	0.8-1.6	1.6-3.1	6.2-12.5	0.8-1.6	6.2-12.5	1.6-3.1
BP473	3.1-6.2	6.2-12.5	1.6-3.1	1.6-3.1	3.1-6.2	1.6-3.1	>25	0.8-1.6
BP387	3.1-6.2	3.1-6.2	3.1-6.2	1.6-3.1	3.1-6.2	1.6-3.1	6.2-12.5	0.8-1.6
BP474	6.2-12.5	3.1-6.2	3.1-6.2	6.2-12.5	1.6-3.1	3.1-6.2	3.1-6.2	0.8-1.6
BP388	3.1-6.2	6.2-12.5	3.1-6.2	1.6-3.1	6.2-12.5	1.6-3.1	6.2-12.5	0.8-1.6
BP499	3.1-6.2	6.2-12.5	3.1-6.2	3.1-6.2	3.1-6.2	1.6-3.1	1.6-3.1	0.8-1.6
BP389	3.1-6.2	6.2-12.5	0.8-1.6	1.6-3.1	3.1-6.2	0.8-1.6	6.2-12.5	1.6-3.1
BP475	3.1-6.2	3.1-6.2	0.8-1.6	1.6-3.1	1.6-3.1	1.6-3.1	3.1-6.2	0.8-1.6
BP390	3.1-6.2	6.2-12.5	6.2-12.5	3.1-6.2	6.2-12.5	3.1-6.2	6.2-12.5	0.8-1.6
BP496	6.2-12.5	6.2-12.5	1.6-3.1	12.5-25	3.1-6.2	12.5-25	3.1-6.2	1.6-3.1
BP394	12.5-25	6.2-12.5	1.6-3.1	0.8- 1.6	6.2-12.5	1.6-3.1	12.5-25	6.2-12.5
BP500	6.2-12.5	3.1-6.2	1.6-3.1	1.6-3.1	3.1-6.2	0.8-1.6	6.2-12.5	3.1-6.2
BP395	12.5-25	3.1-6.2	1.6-3.1	1.6-3.1	3.1-6.2	1.6-3.1	12.5-25	6.2-12.5
BP488	6.2-12.5	3.1-6.2	1.6-3.1	1.6-3.1	3.1-6.2	1.6-3.1	12.5-25	>25
BP398	>25	3.1-6.2	1.6-3.1	3.1-6.2	3.1-6.2	0.8-1.6	>25	6.2-12.5
BP489	6.2-12.5	3.1-6.2	1.6-3.1	3.1-6.2	3.1-6.2	1.6-3.1	12.5-25	>25
BP399	>25	3.1-6.2	1.6-3.1	3.1-6.2	3.1-6.2	0.8-1.6	12.5-25	6.2-12.5
BP490	>25	6.2-12.5	1.6-3.1	1.6-3.1	3.1-6.2	1.6-3.1	12.5-25	>25
BP400	>25	>25	1.6-3.1	3.1-6.2	>25	1.6-3.1	>25	6.2-12.5
BP497	>25	>25	1.6-3.1	0.8-1.6	>25	1.6-3.1	12.5-25	>25
BP402	3.1-6.2	3.1-6.2	1.6-3.1	3.1-6.2	3.1-6.2	1.6-3.1	12.5-25	6.2-12.5
BP476	6.2-12.5	6.2-12.5	1.6-3.1	1.6-3.1	1.6-3.1	1.6-3.1	12.5-25	12.5-25

^aFor each group of peptides, the top sequence corresponds to the all-L derivative

^b*Ea*, *Erwinia amylovora*; *Pss*, *Pseudomonas syringae* pv. *syringae*; *Xap*, *Xanthomonas arboricola* pv. *pruni*; *Xf*, *Xanthomonas fragariae*; *Psa*, *Pseudomonas syringae* pv. *actinidiae*; *Xav*, *Xanthomonas axonopodis* pv. *vesicatoria*; *Pe*, *Penicillium expansum*; *Fo*, *Fusarium oxysporum*.

Table S2. Hemolytic activity

Lipopeptide ^a	Hemolysis (%) ^b			
	50 μ M	150 μ M	250 μ M	375 μ M
BP367	89 \pm 2	87 \pm 14	83 \pm 6	95 \pm 13
BP472	21 \pm 5	66 \pm 3	78 \pm 5	90 \pm 3
BP371	22 \pm 4	47 \pm 2	75 \pm 4	95 \pm 3
BP484	3 \pm 0.1	5 \pm 0.9	10 \pm 2	15 \pm 4
BP374	4 \pm 2	8 \pm 0.4	19 \pm 3	28 \pm 2
BP494	0 \pm 0.5	0.3 \pm 0.8	0.2 \pm 0.2	0.4 \pm 0.5
BP378	15 \pm 7	21 \pm 2	26 \pm 0.4	52 \pm 6
BP495	0 \pm 0.4	0 \pm 0.4	0.6 \pm 1	1 \pm 2
BP379	60 \pm 10	86 \pm 2	93 \pm 0.8	96 \pm 1
BP485	9 \pm 0.4	16 \pm 4	24 \pm 9	46 \pm 5
BP381	11 \pm 2	30 \pm 3	54 \pm 6	76 \pm 2
BP486	3 \pm 2	6 \pm 2	14 \pm 5	14 \pm 2
BP384	41 \pm 15	97 \pm 10	100 \pm 4	100 \pm 2
BP498	6 \pm 1	17 \pm 2	21 \pm 3	36 \pm 2
BP385	42 \pm 3	98 \pm 8	100 \pm 3	100 \pm 4
BP473	7 \pm 2	41 \pm 4	84 \pm 11	75 \pm 12
BP387	4 \pm 0.9	11 \pm 5	14 \pm 0.5	18 \pm 1
BP474	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0
BP388	10 \pm 1	32 \pm 3	38 \pm 4	89 \pm 10
BP499	3 \pm 0.8	7 \pm 0.3	11 \pm 1	17 \pm 1
BP389	9 \pm 4	17 \pm 0.7	22 \pm 2	39 \pm 3
BP475	0 \pm 0	0 \pm 0	0 \pm 0	0 \pm 0
BP390	1 \pm 0.2	2 \pm 0.2	5 \pm 0.3	7 \pm 0.9
BP496	0 \pm 1	0 \pm 0.2	1 \pm 1	1 \pm 0.5
BP394	100 \pm 7	100 \pm 7	100 \pm 1	100 \pm 2
BP500	74 \pm 5	71 \pm 2	71 \pm 8	77 \pm 5
BP395	100 \pm 2	100 \pm 2	100 \pm 2	100 \pm 2
BP488	71 \pm 2	84 \pm 9	86 \pm 14	82 \pm 7
BP398	70 \pm 18	100 \pm 9	100 \pm 3	100 \pm 5
BP489	50 \pm 5	83 \pm 15	100 \pm 6	100 \pm 1
BP399	94 \pm 8	100 \pm 5	100 \pm 5	100 \pm 6
BP490	100 \pm 3	92 \pm 17	100 \pm 6	98 \pm 2
BP400	43 \pm 3	56 \pm 1	99 \pm 0.4	100 \pm 14
BP497	88 \pm 14	100 \pm 2	100 \pm 2	100 \pm 4
BP402	95 \pm 6	93 \pm 13	100 \pm 4	100 \pm 0.5
BP476	69 \pm 3	79 \pm 7	94 \pm 10	94 \pm 67

^aFor each group of peptides, the top sequence corresponds to the all-L derivative

^bPercent hemolysis plus confidence interval ($\alpha = 0.05$)

Table S3. Size of the lesion in infiltrated tobacco leaves

Lipopeptide ^a	Size of the lesion (mm) ^b		
	50 μ M	150 μ M	250 μ M
BP367	6 \pm 0.4	9 \pm 2	15 \pm 4
BP472	2 \pm 1	4 \pm 1	4 \pm 1
BP371	2 \pm 0.5	-	9 \pm 2
BP484	0 \pm 0	2 \pm 2	7 \pm 1
BP374	3 \pm 0.6	9 \pm 2	12 \pm 3
BP494	1 \pm 1	6 \pm 1	8 \pm 1
BP378	4 \pm 0.7	12 \pm 3	13 \pm 5
BP495	3 \pm 0	6 \pm 2	11 \pm 2
BP379	7 \pm 1	13 \pm 3	16 \pm 3
BP485	4 \pm 0.7	7 \pm 0.7	12 \pm 1
BP381	5 \pm 2	11 \pm 2	11 \pm 2
BP486	4 \pm 1	8 \pm 1	17 \pm 2
BP384	8 \pm 1	11 \pm 3	11 \pm 2
BP498	4 \pm 3	6 \pm 2	6 \pm 1
BP385	8 \pm 1	13 \pm 2	13 \pm 2
BP473	2 \pm 2	4 \pm 0.9	5 \pm 2
BP387	3 \pm 0.7	8 \pm 1	9 \pm 1
BP474	0 \pm 0	2 \pm 2	4 \pm 2
BP388	8 \pm 2	11 \pm 0.4	10 \pm 3
BP499	6 \pm 1	8 \pm 2	8 \pm 2
BP389	4 \pm 1	7 \pm 1	9 \pm 3
BP475	5 \pm 1	7 \pm 2	10 \pm 1
BP390	3 \pm 0.7	7 \pm 1	8 \pm 2
BP496	3 \pm 0.5	4 \pm 0.5	10 \pm 3
BP394	3 \pm 0.7	12 \pm 1	13 \pm 0.6
BP500	3 \pm 2	6 \pm 2	9 \pm 3
BP395	8 \pm 0.7	11 \pm 2	10 \pm 3
BP488	4 \pm 0.7	5 \pm 1	13 \pm 5
BP398	5 \pm 0.5	9 \pm 2	11 \pm 4
BP489	2 \pm 0.5	6 \pm 2	11 \pm 1
BP399	5 \pm 0.8	8 \pm 2	10 \pm 3
BP490	4 \pm 0.7	6 \pm 2	11 \pm 3
BP400	7 \pm 1	11 \pm 2	15 \pm 4
BP497	5 \pm 1	18 \pm 1	18 \pm 0
BP402	4 \pm 1	10 \pm 2	9 \pm 2
BP476	3 \pm 0.6	3 \pm 0.5	5 \pm 0.5

^aFor each group of peptides, the top sequence corresponds to the all-L derivative

^bEffect on the size of the lesion in infiltrated tobacco leaves plus confidence interval

2. Synthesis of lipopeptides

C₅H₁₁CO-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP472)

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (75:25) afforded C₅H₁₁CO-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (**BP472**) in >99% purity. *t_R* = 6.14 min. MS (ESI) *m/z*: 760.1 [M + 2H]²⁺, 1519.1 [M + H]⁺; HRMS (ESI) *m/z*: calcd for C₇₈H₁₃₇N₁₇O₁₃ [M + 2H]²⁺ 760.0285, found 760.0260; calcd for C₇₈H₁₃₆N₁₇O₁₃ [M + H]⁺ 1519.0498, found 1519.0511.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys(COC₃H₇)-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP473)

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (75:25) afforded Ac-Lys-Lys-Leu-D-Phe-Lys-Lys(COC₃H₇)-Ile-Leu-Lys-Tyr-Leu-NH₂ (**BP473**) in >99% purity. *t_R* = 5.99 min. MS (ESI) *m/z*: 767.1 [M + 2H]²⁺, 1533.1 [M + H]⁺, 1555.1 [M + Na]⁺; HRMS (ESI) *m/z*: calcd for C₇₈H₁₃₅N₁₇O₁₄ [M + 2H]²⁺ 767.0182, found 767.0158; calcd for C₇₈H₁₃₄N₁₇O₁₄ [M + H]⁺ 1533.0291, found 1533.0240.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Lys(COC₃H₇)-Lys-Tyr-Leu-NH₂ (BP474)

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (85:15) afforded Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Lys(COC₃H₇)-Lys-Tyr-Leu-NH₂ (**BP474**) in >99% purity. *t_R* = 5.36 min. MS (ESI) *m/z*: 774.6 [M + 2H]²⁺, 1548.1 [M + H]⁺, 1570.1 [M + Na]⁺; HRMS (ESI) *m/z*: calcd for C₇₈H₁₃₆N₁₈O₁₄ [M + 2H]²⁺ 774.5236, found 774.5208; calcd for C₇₈H₁₃₅N₁₈O₁₄ [M + H]⁺ 1548.0400, found 1548.0381.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC₃H₇)-Leu-NH₂ (BP475)

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (80:20) afforded

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC₃H₇)-Leu-NH₂ (**BP475**) in >99% purity. t_R = 5.69 min. MS (ESI) m/z : 750.1 [M + 2H]²⁺, 1498.2 [M + H]⁺, 1520.1 [M + Na]⁺; HRMS (ESI) m/z : calcd for C₇₅H₁₃₈N₁₈O₁₃ [M + 2H]²⁺ 749.5340, found 749.5343; calcd for C₇₅H₁₃₇N₁₈O₁₃ [M + H]⁺ 1498.0607, found 1498.0610; calcd for C₇₅H₁₃₆N₁₈O₁₃Na [M + Na]⁺ 1520.0426, found 1520.0424.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC₁₁H₂₃)-NH₂ (BP476)

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (80:20) afforded Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC₁₁H₂₃)-NH₂ (**BP476**) in >99% purity. t_R = 6.67 min. MS (ESI) m/z : 830.6 [M + 2H]²⁺, 1660.3 [M + H]⁺, 1682.2 [M + Na]⁺; HRMS (ESI) m/z : calcd for C₈₆H₁₅₂N₁₈O₁₄ [M + 2H]²⁺ 830.5862, found 830.5839; calcd for C₈₆H₁₅₁N₁₈O₁₄ [M + H]⁺ 1660.1652, found 1660.1578.

Ac-Lys-Lys-Leu-D-Lys(COC₅H₁₁)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP484)

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (80:20) afforded Ac-Lys-Lys-Leu-D-Lys(COC₅H₁₁)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (**BP484**) in >99% purity. t_R = 6.45 min. MS (ESI) m/z : 771.5 [M + 2H]²⁺, 1542.0 [M + H]⁺; HRMS (ESI) m/z : calcd for C₇₇H₁₄₂N₁₈O₁₄ [M + 2H]²⁺ 771.5471, found 771.5477; calcd for C₇₇H₁₄₁N₁₈O₁₄ [M + H]⁺ 1542.0869, found 1542.0812.

C₃H₇CO-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP485)

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (75:25) afforded C₃H₇CO-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (**BP485**) in >99% purity. t_R = 6.79 min. MS (ESI) m/z : 746.4 [M + 2H]²⁺, 1491.0 [M + H]⁺, 1513.1 [M + Na]⁺; HRMS (ESI) m/z : calcd for C₇₆H₁₃₃N₁₇O₁₃ [M + 2H]²⁺ 746.0129, found 746.0097; calcd for C₇₆H₁₃₂N₁₇O₁₃ [M + H]⁺ 1491.0185, found 1491.0154.

Ac-Lys-Lys(COC₃H₇)-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP486)

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (75:25) afforded Ac-Lys-Lys(COC₃H₇)-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (**BP486**) in >99% purity. t_R = 6.17 min. MS (ESI) m/z : 767.1 [M + 2H]²⁺, 1533.1 [M + H]⁺; HRMS (ESI) m/z : calcd for C₇₈H₁₃₄N₁₇O₁₄ [M + H]⁺ 1533.0291, found 1533.0266; calcd for C₇₈H₁₃₃N₁₇O₁₄Na [M + Na]⁺ 1555.0110, found 1555.0071.

Ac-Lys-Lys-Leu-D-Lys(COC₁₁H₂₃)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP488)

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (75:25) afforded Ac-Lys-Lys-Leu-D-Lys(COC₁₁H₂₃)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (**BP488**) in >99% purity. t_R = 6.80 min. MS (ESI) m/z : 814.1 [M + 2H]²⁺, 1626.2 [M + H]⁺; HRMS (ESI) m/z : calcd for C₈₃H₁₅₃N₁₈O₁₄ [M + H]⁺ 1626.1808, found 1626.1787; calcd for C₈₃H₁₅₂N₁₈O₁₄Na [M + Na]⁺ 1648.1628, found 1648.1600.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Lys(COC₁₁H₂₃)-Leu-Lys-Tyr-Leu-NH₂ (BP489)

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (75:25) afforded Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Lys(COC₁₁H₂₃)-Leu-Lys-Tyr-Leu-NH₂ (**BP489**) in >99% purity. t_R = 6.76 min. MS (ESI) m/z : 554.4 [M + 3H]³⁺, 831.1 [M + 2H]²⁺, 1660.2 [M + H]⁺; HRMS (ESI) m/z : calcd for C₈₆H₁₅₂N₁₈O₁₄ [M + 2H]²⁺ 830.5862, found 830.5825; calcd for C₈₆H₁₅₁N₁₈O₁₄ [M + H]⁺ 1660.1652, found 1660.1598.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Lys(COC₁₁H₂₃)-Lys-Tyr-Leu-NH₂ (BP490)

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (75:25) afforded Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Lys(COC₁₁H₂₃)-Lys-Tyr-Leu-NH₂ (**BP490**) in >99% purity. t_R

= 7.12 min. MS (ESI) m/z : 554.4 $[M + 3H]^{3+}$, 831.1 $[M + 2H]^{2+}$, 1660.2 $[M + H]^+$; HRMS (ESI) m/z : calcd for $C_{86}H_{151}N_{18}O_{14}$ $[M + H]^+$ 1660.1652, found 1660.1635; calcd for $C_{86}H_{150}N_{18}O_{14}Na$ $[M + Na]^+$ 1682.1471, found 1682.1449.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Lys(COC₅H₁₁)-Leu-Lys-Tyr-Leu-NH₂ (BP494)

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (80:20) afforded Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Lys(COC₅H₁₁)-Leu-Lys-Tyr-Leu-NH₂ (**BP494**) in >99% purity. t_R = 5.42 min. MS (ESI) m/z : 788.6 $[M + 2H]^{2+}$, 1576.1 $[M + H]^+$; HRMS (ESI) m/z : calcd for $C_{80}H_{139}N_{18}O_{14}$ $[M + H]^+$ 1576.0713, found 1576.0683; calcd for $C_{80}H_{138}N_{18}O_{14}Na$ $[M + Na]^+$ 1598.0532, found 1598.0490.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC₅H₁₁)-NH₂ (BP495)

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (80:20) afforded Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC₅H₁₁)-NH₂ (**BP495**) in >99% purity. t_R = 5.44 min. MS (ESI) m/z : 789.1 $[M + 2H]^{2+}$, 1576.1 $[M + H]^+$; HRMS (ESI) m/z : calcd for $C_{80}H_{139}N_{18}O_{14}$ $[M + H]^+$ 1576.0713, found 1576.0683; calcd for $C_{80}H_{138}N_{18}O_{14}Na$ $[M + Na]^+$ 1598.0532, found 1598.0499.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC₃H₇)-NH₂ (BP496)

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (80:20) afforded Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC₃H₇)-NH₂ (**BP496**) in >99% purity. t_R = 5.11 min. MS (ESI) m/z : 775.1 $[M + 2H]^{2+}$, 1548.2 $[M + H]^+$, 1570.1 $[M + Na]^+$; HRMS (ESI) m/z : calcd for $C_{86}H_{135}N_{18}O_{14}$ $[M + H]^+$ 1548.0400, found 1548.0367; calcd for $C_{78}H_{134}N_{18}O_{14}Na$ $[M + Na]^+$ 1570.0219, found 1570.0179.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys(COC₁₁H₂₃)-Tyr-Leu-NH₂ (BP497)

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (75:25) afforded Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys(COC₁₁H₂₃)-Tyr-Leu-NH₂ (**BP497**) in >99% purity. t_R = 7.21 min. MS (ESI) m/z : 823.1 [M + 2H]²⁺, 1645.1 [M + H]⁺; HRMS (ESI) m/z : calcd for C₈₆H₁₅₀N₁₇O₁₄ [M + H]⁺ 1645.1543, found 1645.1516; calcd for C₈₆H₁₄₉N₁₇O₁₄Na [M + Na]⁺ 1667.1362, found 1667.1311.

Ac-Lys-Lys-Leu-D-Phe-Lys(COC₃H₇)-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP498)

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (70:30) afforded Ac-Lys-Lys-Leu-D-Phe-Lys(COC₃H₇)-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (**BP498**) in >99% purity. t_R = 6.12 min. MS (ESI) m/z : 767.0 [M + 2H]²⁺, 1533.1 [M + H]⁺; HRMS (ESI) m/z : calcd for C₇₈H₁₃₅N₁₇O₁₄ [M + 2H]²⁺ 767.0182, found 767.0147; calcd for C₇₈H₁₃₄N₁₇O₁₄ [M + H]⁺ 1533.0291, found 1533.0225; calcd for C₇₈H₁₃₃N₁₇O₁₄Na [M + Na]⁺ 1555.0110, found 1555.0032.

Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys(COC₃H₇)-Tyr-Leu-NH₂ (BP499)

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (75:25) afforded Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys(COC₃H₇)-Tyr-Leu-NH₂ (**BP499**) in >99% purity. t_R = 5.89 min. MS (ESI) m/z : 766.8 [M + 2H]²⁺, 1533.4 [M + H]⁺, 1555.1 [M + Na]⁺; HRMS (ESI) m/z : : calcd for C₇₈H₁₃₄N₁₇O₁₄ [M + H]⁺ 1533.0291, found 1533.0269; calcd for C₇₈H₁₃₃N₁₇O₁₄Na [M + Na]⁺ 1555.0110, found 1555.0097.


Ac-Lys-Lys-Lys(COC₁₁H₂₃)-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP500)

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H₂O/CH₃CN (70:30) afforded Ac-Lys-Lys-Lys(COC₁₁H₂₃)-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (**BP500**) in >99% purity. t_R


= 6.80 min. MS (ESI) m/z : 554.4 $[M + 3H]^{3+}$, 830.7 $[M + 2H]^{2+}$; HRMS (ESI) m/z : calcd for $C_{86}H_{151}N_{18}O_{14}$ $[M + H]^+$ 1661.1684, found 1661.1667; calcd for $C_{86}H_{150}N_{18}O_{14}Na$ $[M + Na]^+$ 1683.1503, found 1683.1487.

3. HPLC of crude and purified lipopeptides, ESI-MS and HRMS of purified lipopeptides

$C_5H_{11}CO$ -Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu- NH_2 (BP472)




HPLC of crude peptide ($\lambda=220$ nm)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.305	VV	0.0871	334.45099	54.91665	2.8671
2	5.491	VB	0.0577	135.30244	32.39536	1.1599
3	6.179	BV R	0.0529	1.00572e4	2871.68335	86.2160
4	6.354	VB E	0.0962	953.29431	126.04663	8.1722
5	7.540	VV R	0.0572	184.87265	46.71790	1.5848



HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys-Lys(COC₃H₇)-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP473)




HPLC of crude peptide ($\lambda=220$ nm)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.254	BV R	0.0464	8589.29297	2749.92847	77.4871
2	6.408	VB E	0.0496	383.71664	115.83309	3.4616
3	6.769	BV	0.0511	1300.70288	369.00027	11.7341
4	6.830	WV R	0.0589	811.08887	182.18036	7.3171



HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Lys(COC₃H₇)-Lys-Tyr-Leu-NH₂ (BP474)




HPLC of crude peptide ($\lambda=220$ nm)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.129	BV E	0.0323	377.93021	181.34412	2.2820
2	5.196	VV E	0.0268	212.25146	119.26482	1.2816
3	5.253	VB R	0.0595	1.16522e4	3125.37207	70.3588
4	5.434	BB	0.0460	1109.19092	349.34921	6.6976
5	5.883	BV E	0.0659	192.02771	38.04109	1.1595
6	5.962	WV R	0.0532	2679.02954	707.11737	16.1766
7	6.472	BB	0.0410	95.51791	34.79841	0.5768
8	7.520	VB R	0.0507	242.96144	71.34217	1.4671



HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC₃H₇)-Leu-NH₂ (BP475)




HPLC of crude peptide ($\lambda=220$ nm)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.634	VV R	0.0514	6206.26611	1748.02429	81.1357
2	5.852	VB E	0.0914	327.03192	50.62853	4.2753
3	6.374	VB R	0.0767	938.12811	166.53392	12.2643
4	7.533	VV R	0.0512	177.81927	52.87458	2.3247



HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)







Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC₁₁H₂₃)-NH₂ (BP476)




HPLC of crude peptide ($\lambda=220$ nm)





HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Lys(COC₅H₁₁)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP484)




HPLC of crude peptide ($\lambda=220$ nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,21	83,361	5,410	2,75
2	6,35	62,693	3,161	1,61
3	6,45	1725,101	147,916	75,14
4	6,78	441,976	34,458	17,50
5	7,45	13,446	0,734	0,37
6	7,95	63,681	5,177	2,63
Total:		2390,257	196,857	100,00

HPLC of purified peptide ($\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,45	467,768	30,006	100,00
Total:		467,768	30,006	100,00

ESI-MS (m/z)




HRMS (m/z)






C₃H₇CO-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP485)




HPLC of crude peptide ($\lambda=220$ nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,80	218,320	17,258	52,25
2	7,62	38,563	3,368	10,20
3	7,98	176,249	12,401	37,55
Total:		433,132	33,026	100,00

HPLC of purified peptide ($\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,79	651,352	44,377	100,00
Total:		651,352	44,377	100,00

ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys(COC₃H₇)-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP486)




HPLC of crude peptide ($\lambda=220$ nm)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.671	BB	0.0522	143.78764	39.70819	3.1093
2	6.141	VV R	0.0479	3568.24097	1098.94568	77.1617
3	6.344	VB E	0.0628	284.22037	63.95224	6.1461
4	6.632	VB R	0.0526	628.11932	172.08841	13.5828


Totals : 4624.36830 1374.69452

HPLC of purified peptide ($\lambda=220$ nm)






Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.173	BB	0.0634	9405.44824	2219.42041	100.0000
Totals :				9405.44824	2219.42041	

ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Lys(COC₁₁H₂₃)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP488)




HPLC of crude peptide ($\lambda=220$ nm)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.088	BV R	0.0441	1046.76038	347.67551	12.7178
2	6.255	VB E	0.0670	154.87279	33.46687	1.8817
3	6.485	BB	0.0487	202.15788	62.57148	2.4562
4	6.821	VV R	0.0686	6048.61426	1316.82983	73.4888
5	6.991	VB E	0.0507	778.25232	228.61604	9.4555

Totals : 8230.65762 1989.15973



HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Lys(COC₁₁H₂₃)-Leu-Lys-Tyr-Leu-NH₂ (BP489)




HPLC of crude peptide ($\lambda=220$ nm)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.945	WV R	0.0468	694.77289	214.59721	12.4485
2	6.745	BV R	0.0579	4328.80762	1099.50281	77.5611
3	6.908	WV E	0.0672	426.74368	87.06355	7.6461
4	7.619	VB R	0.0553	130.83649	36.04453	2.3443


Totals : 5581.16068 1437.20810

HPLC of purified peptide ($\lambda=220$ nm)






Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.755	BB	0.0665	7391.91846	1673.21887	100.0000
Totals :				7391.91846	1673.21887	

ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Lys(COC₁₁H₂₃)-Lys-Tyr-Leu-NH₂ (BP490)




HPLC of crude peptide ($\lambda=220$ nm)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.275	BV R	0.0575	723.08496	181.44606	12.9286
2	7.141	BV R	0.0729	4869.80566	948.12061	87.0714
Totals :				5592.89063	1129.56667	




HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Lys(COC₅H₁₁)-Leu-Lys-Tyr-Leu-NH₂ (BP494)




HPLC of crude peptide ($\lambda=220$ nm)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.423	WV R	0.0340	2517.67651	1130.30176	80.8293
2	5.619	VB E	0.0374	84.14298	34.50963	2.7014
3	5.869	WV R	0.0346	432.04156	189.79099	13.8706
4	6.919	WV R	0.0340	80.94740	36.32489	2.5988

Totals : 3114.80846 1390.92727



HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC₅H₁₁)-NH₂ (BP495)




HPLC of crude peptide ($\lambda=220$ nm)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.412	VV R	0.0356	3169.20239	1389.56665	75.7298
2	5.563	VB	0.0487	535.45313	174.93906	12.7949
3	5.930	BV R	0.0353	480.22589	204.92200	11.4753


Totals : 4184.88141 1769.42770

HPLC of purified peptide ($\lambda=220$ nm)






Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.440	VB R	0.0545	1.04920e4	3101.66650	100.0000
Totals :				1.04920e4	3101.66650	

ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC₃H₇)-NH₂ (BP496)




HPLC of crude peptide ($\lambda=220$ nm)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.053	VB R	0.0325	1323.29224	630.92993	86.8886
2	5.952	VV R	0.0419	199.68292	70.85992	13.1114
Totals :				1522.97516	701.78985	



HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys(COC₁₁H₂₃)-Tyr-Leu-NH₂ (BP497)




HPLC of crude peptide ($\lambda=220$ nm)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.241	VB R	0.0399	431.05203	157.88124	12.7336
2	7.245	W R	0.0556	2954.10278	772.97687	87.2664

Totals : 3385.15482 930.85811



HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys(COC₃H₇)-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP498)




HPLC of crude peptide ($\lambda=220$ nm)




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.487	VB R	0.0464	148.45491	45.10777	1.0160
2	6.149	VV R	0.0632	1.10937e4	2578.84717	75.9247
3	6.340	VV E	0.0510	902.96692	250.56866	6.1799
4	6.634	BV R	0.0567	2112.34912	528.10651	14.4569
5	6.785	VV E	0.0489	152.63356	43.54723	1.0446
6	7.551	VV	0.0518	201.33051	57.53705	1.3779

Totals : 1.46114e4 3503.71439



HPLC of purified peptide ($\lambda=220$ nm)




ESI-MS (m/z)




HRMS (m/z)






Ac-Lys-Lys-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys(COC₃H₇)-Tyr-Leu-NH₂ (BP499)




HPLC of crude peptide ($\lambda=220$ nm)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.866	VB R	0.0443	5598.51953	1849.33667	77.5439
2	6.050	BB	0.0433	478.38898	162.94824	6.6261
3	6.213	BB	0.0390	849.00946	329.78500	11.7594
4	6.313	BV	0.0370	90.36411	37.69422	1.2516
5	7.573	BV R	0.0764	203.52594	36.29560	2.8190

Totals : 7219.80802 2416.05974


HPLC of purified peptide ($\lambda=220$ nm)





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.892	BV R	0.0617	1.23197e4	2951.55957	100.0000

Totals : 1.23197e4 2951.55957


ESI-MS (m/z)




HRMS (m/z)



Ac-Lys-Lys(COC₁₁H₂₃)-Leu-D-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH₂ (BP500)




HPLC of crude peptide ($\lambda=220$ nm)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.889	BV R	0.0428	573.98651	192.62531	2.2259
2	5.177	VB	0.0478	194.40025	56.93281	0.7539
3	5.445	VB R	0.0522	155.32494	41.03360	0.6023
4	5.683	BV	0.0402	88.94859	32.20647	0.3449
5	5.724	VB	0.0343	124.03711	52.92344	0.4810
6	6.037	BV R	0.0531	4459.11426	1236.56287	17.2920
7	6.191	VB E	0.0551	397.45981	102.88657	1.5413
8	6.820	BV R	0.0960	1.77881e4	2804.05859	68.9804
9	7.012	VV E	0.0503	1283.47070	371.63638	4.9772
10	7.396	BB	0.0442	159.22202	52.83167	0.6174
11	7.501	BV	0.0502	202.72284	65.27905	0.7861
12	7.550	VB	0.0532	360.41031	97.30477	1.3976


Totals : 2.57872e4 5106.28153

HPLC of purified peptide ($\lambda=220$ nm)






Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.795	BV R	0.0854	1.51681e4	2586.43701	100.0000
Totals :				1.51681e4	2586.43701	

ESI-MS (m/z)



HRMS (m/z)



4. NMR experiments of lipopeptides BP389 and BP475

BP389

¹H-NMR (400 MHz, 20 mM phosphate buffer pH = 6.5 H₂O/D₂O (90:10)) δ (ppm): 0.77-0.89 (m, 29H, CH₃-butanoyl, δ -CH₃-Ile, 6 \times δ -CH₃-Leu, γ -CH₃-Ile, δ -CH₂-Lys), 1.22-1.81 (m, 48 H, β -CH₂-butanoyl, β -CH₂-Ile, γ -CH₂-Ile, 3 \times β -CH₂-Leu, 3 \times γ -CH-Leu, 6 \times β -CH₂-Lys, 6 \times γ -CH₂-Lys, 5 \times δ -CH₂-Lys), 1.97 (s, 3H, CH₃CO), 2.14 (t, J = 7.57 Hz, 2H, α -CH₂-butanoyl), 2.88-3.02 (m, 12H, 5 \times ϵ -CH₂-Lys, β -CH₂-Phe), 3.09-3.16 (m, 2H, ϵ -CH₂-Lys¹⁰), 4.03-4.07 (m, 1H, α -CH-Ile), 4.12-4.33 (m, 5H, 5 \times α -CH-Lys, α -CH-Lys¹⁰, 3 \times α -CH-Leu), 4.52-4.55 (m, α -CH-Phe), 7.09 (s, 1H, CONH₂), 7.18 (d, J = 6.96 Hz, 2H, 2 \times o -CH-Phe_{arom}), 7.22-7.31 (m, 3H, 2 \times m -CH-Phe_{arom}, p -CH-Phe_{arom}), 7.58 (s, 1H, CONH₂), 8.02 (t, J = 5.94 Hz, 1H, ζ -NH-Lys¹⁰), 8.16-8.22 (m, 3H, α -NH-Phe, α -NH-Leu, α -NH-Lys), 8.29-8.36 (m, 6H, 4 \times α -NH-Lys, α -NH-Ile, α -NH-Leu), 8.40-8.42 (m, 2H, α -NH-Lys¹⁰, α -NH-Leu).

¹H-NMR (400 MHz, 20 mM phosphate buffer at pH = 6.5 with H₂O/D₂O (90:10) containing 30% CF₃CD₂OD) δ (ppm): 0.69-0.72 (m, 6H, 2 \times δ -CH₃-Leu⁸), 0.77-0.92 (m, 18H, 2 \times δ -CH₃-Leu¹¹, δ -CH₃-Ile⁷, δ -CH₃-Leu³, CH₃-butanoyl, δ ¹-CH₃-Leu³), 1.03-1.11 (m, 3H, γ -CH₃-Ile⁷), 1.35-1.98 (m, 48H, γ -CH-Leu⁸, δ -CH₂-Lys¹, δ -CH₂-Lys², δ -CH₂-Lys⁵, δ -CH₂-Lys⁶, δ -CH₂-Lys⁹, δ -CH₂-Lys¹⁰, γ -CH-Leu¹¹, β -CH₂-butanoyl, γ -CH-Leu³, γ -CH₂-Lys¹, γ -CH₂-Lys², γ -CH₂-Lys⁵, γ -CH₂-Lys⁶, γ -CH₂-Lys⁹, γ -CH₂-Lys¹⁰, β -CH-Leu⁸, γ -CH₂-Ile⁷, β -CH-Leu³, β -CH₂-Lys¹, β -CH₂-Lys², β -CH₂-Lys⁵, β -CH₂-Lys⁶, β -CH₂-Lys⁹, β -CH₂-Lys¹⁰, β -CH₂-Leu¹¹, β -CH-Ile⁷), 2.03 (s, 3H, CH₃CO), 2.13 (t, J = 7.48 Hz, 2H, α -CH₂-butanoyl), 2.91-3.00 (m, 10 H, ϵ -CH₂-Lys¹, ϵ -CH₂-Lys², ϵ -CH₂-Lys⁵, ϵ -CH₂-Lys⁶, ϵ -CH₂-Lys⁹), 3.08-3.16 (m, 4 H, ϵ -CH₂-Lys¹⁰, β -CH₂-Phe⁴), 3.59 (br, 1H, α -CH-Ile⁷), 3.84-4.24 (m, 10H, α -CH-Lys⁵, α -CH-Leu⁸, α -CH-Lys⁶, α -CH-Lys¹, α -CH-Lys², α -CH-Lys⁹, α -CH-Lys¹⁰, α -CH-Leu¹¹, α -CH-Leu³, α -CH-Phe⁴), 6.96 (s, 1H, CONH₂), 7.10 (d, J = 7.01 Hz, 2H, 2 \times o -CH-Phe_{arom}), 7.16-7.21 (m, 4 H, p -CH-Phe_{arom}, 2 \times m -CH-Phe_{arom}, CONH₂), 7.57 (br, 1H, α -NH-Leu³), 7.59 (br, 1H, α -NH-Lys⁶), 7.73 (br, 1H, α -NH-Lys⁹), 7.83 (br, 1H, α -NH-Lys¹⁰), 8.07-8.10 (m, 3H, α -NH-Leu¹¹, α -NH-Ile⁷, α -NH-Phe⁴), 8.13 (br, 1H, α -NH-Lys⁵), 8.26 (br, 1H, α -NH-Leu⁸), 8.36 (br, 1H, α -NH-Lys¹), 8.42 (br, 1H, α -NH-Lys²).

BP475

¹H-NMR (400 MHz, 20 mM phosphate buffer pH = 6.5 H₂O/D₂O (90:10)) δ (ppm): 0.75-0.90 (m, 24H, CH₃-butanoyl, δ -CH₃-Ile, 6 \times δ -CH₃-Leu), 0.99-1.16 (m, 5H, γ -CH₃-Ile, δ -CH₂-Lys), 1.25-1.82 (m, 48 H, β -CH₂-butanoyl, β -CH₂-Ile, γ -CH₂-Ile, 3 \times β -CH₂-Leu, 3 \times γ -CH-Leu, 6 \times β -CH₂-Lys, 6 \times γ -CH₂-Lys, 5 \times δ -CH₂-Lys), 1.98 (s, 3H, CH₃CO), 2.15 (t, J = 7.48 Hz, 2H, α -CH₂-butanoyl), 2.85-3.00 (m, 11H, 5 \times ϵ -CH₂-Lys, β -CH₂-Phe), 3.06-3.16 (m, 3H, ϵ -CH₂-Lys¹⁰, β -CH₂-Phe), 4.06-4.13 (m, 2H, α -CH-Ile, α -CH-Lys), 4.15-4.34 (m, 5H, 4 \times α -CH-Lys, α -CH-Lys¹⁰, 3 \times α -CH-Leu), 4.54-4.57 (m, α -CH-Phe), 7.11 (s, 1H, CONH₂), 7.21 (d, J = 7.16 Hz, 2H, 2 \times *o*-CH-Phe_{arom}), 7.26-7.36 (m, 3H, 2 \times *m*-CH-Phe_{arom}, *p*-CH-Phe_{arom}), 7.59 (s, 1H, CONH₂), 8.04 (t, J = 5.82Hz, 1H, ζ -NH-Lys¹⁰), 8.21-8.29 (m, 3H, α -NH-Ile, α -NH-Leu, α -NH-Lys), 8.32-8.46 (m, 6H, α -NH-Lys¹⁰, 4 \times α -NH-Lys, α -NH-Phe, 2 \times α -NH-Leu).

¹H-NMR (400 MHz, 20 mM phosphate buffer at pH = 6.5 with H₂O/D₂O (90:10) containing 30% CF₃CD₂OD)) δ (ppm): 0.82-0.94 (m, 24H, CH₃-butanoyl, 2 \times δ -CH₃-Leu³, 2 \times δ -CH₃-Leu⁸, 2 \times δ -CH₃-Leu¹¹, δ -CH₃-Ile), 1.08-1.31 (m, 3H, γ -CH₃-Ile), 1.33-1.85 (m, 24H, β -CH₂-butanoyl, β -CH₂-Lys⁶, β -CH₂-Leu⁸, β -CH₂-Leu¹¹, δ -CH₂-Lys¹, δ -CH₂-Lys², δ -CH₂-Lys⁶, δ -CH₂-Lys¹⁰, γ -CH₂-Lys¹, γ -CH₂-Lys², γ -CH₂-Lys⁶, γ -CH₂-Ile), 1.95 (s, 7H, β -CH₂-Lys², β -CH₂-Lys¹⁰, CH₃CO), 2.14 (t, J = 7.66 Hz, 2H, α -CH₂-butanoyl), 2.90-2.99 (m, 7 H, ϵ -CH₂-Lys¹, ϵ -CH₂-Lys², ϵ -CH₂-Lys⁶, β -CH₂-Phe), 3.15 (m, 3H, ϵ -CH₂-Lys¹⁰, β -CH₂-Phe), 3.77 (br, 1H, α -CH-Ile), 3.85-4.19 (m, 8 H, α -CH-Lys¹, α -CH-Lys², α -CH-Lys⁶, α -CH-Lys¹⁰, α -CH-Leu³, α -CH-Leu⁸, α -CH-Leu¹¹, α -CH-Phe), 6.94 (s, 1H, CONH₂), 7.08 (d, J = 6.36 Hz, 2H, 2 \times *o*-CH-Phe_{arom}), 7.27-7.18 (m, 4 H, *p*-CH-Phe_{arom}, 2 \times *m*-CH-Phe_{arom}, CONH₂), 7.46-7.43 (m, 1H, ζ -NH-Lys¹⁰), 7.64 (br, 1H, α -NH-Leu³), 7.76 (br, 1H, α -NH-Lys¹⁰), 7.81 (br, 1H, α -NH-Lys⁶), 7.92 (br, 1H, α -NH-Lys⁹), 8.03-8.11 (m, 3H, α -NH-Lys⁵, α -NH-Ile, α -NH-Leu¹¹), 8.15-8.19 (m, 2H, α -NH-Phe, α -NH-Leu⁸), 8.22 (br, 1H, α -NH-Lys¹), 8.30 (br, 1H, α -NH-Lys²).

BP389**Table S4. NMR data of lipopeptide BP389 recorded at 400 MHz in 20 mM phosphate buffer, pH = 6.5 H₂O/D₂O (90:10)**

Amino acid	δ (ppm)					
	CO-NH	CO-NH	α -CH	α -CH	β -CH	β -CH
Phe⁴	8.32	123.8	4.53	54.8	2.97 / 3.01	36.9
Ile⁷	8.34	124.1	4.06	57.9	1.78	35.7
Lys¹⁰	8.41	122.5	4.21	53.2	1.66	38.9
5 × Lys	8.30	123.0	4.19	53.1	1.61	30.5
	8.32	127.0	4.24	53.3	1.70	30.3
	8.32	121.9	4.18	53.5	1.67	30.2
	8.35	123.7	4.13	53.8	1.65	30.2
	8.17	124.0	4.20	53.6	1.46	30.3
	8.21	123.6	4.26	51.8	1.51	39.6
3 × Leu	8.34	124.1	4.29	52.0	1.54	39.6
	8.42	127.8	4.33	52.1	1.61	39.5

Table S5. NMR data of lipopeptide BP389 recorded at 400 MHz in 20 mM phosphate buffer, pH = 6.5 H₂O/D₂O (90:10), containing 30% CF₃CD₂OD

Amino acid	δ (ppm)					
	CO-NH	CO-NH	α -CH	α -CH	β -CH	β -CH
Lys¹	8.36	126.1	4.00	56.6	1.82	29.4
Lys²	8.42	116.8	4.02	56.5	1.82	29.7
Leu³	7.57	124.6	4.15	54.3	1.73	26.6
Phe⁴	8.10	118.2	4.24	57.8	3.10	35.7
Lys⁵	8.13	116.0	3.84	57.0	1.88	29.4
Lys⁶	7.59	118.7	3.99	56.8	2.01	29.5
Ile⁷	8.10	120.2	3.59	62.2	1.92	34.8
Leu⁸	8.26	118.7	3.88	55.1	1.66	26.5
Lys⁹	7.73	117.9	4.02	55.7	1.95	29.2
Lys¹⁰	7.83	119.5	4.04	55.9	1.90	28.0
Leu¹¹	8.07	118.4	4.12	53.0	1.79	

BP475

Table S6. NMR data of lipopeptide BP475 recorded at 400 MHz in 20 mM phosphate buffer, pH = 6.5 H₂O/D₂O (90:10)

Amino acid	δ (ppm)					
	CO-NH	CO-NH	α -CH	α -CH	β -CH	β -CH
Phe⁴	8.40	122.0	4.56	55.3	3.08 / 2.98	36.8
Ile⁷	8.26	122.3	4.08	57.9	1.79	35.6
Lys¹⁰	8.32	122.9	4.24	53.4	1.72	30.3
5 × Lys	8.27	122.7	4.22	53.5	1.68	30.2
	8.34	124.0	4.17	53.8	1.72	30.3
	8.38	124.2	4.10	53.4	1.49	30.1
	8.39	122.7	4.22	53.6	1.72	38.3
	8.45	122.3	4.29	53.2	1.68	30.1
	8.22	123.5	4.25	52.2	1.39	39.8
3 × Leu	8.34	121.0	4.27	52.0	1.62	39.6
	8.42	127.8	4.33	52.1	1.54	39.5


Table S7. NMR data of lipopeptide BP475 recorded at 400 MHz in 20 mM phosphate buffer, pH = 6.5 H₂O/D₂O (90:10), containing 30% CF₃CD₂OD

Amino acid	δ (ppm)					
	CO-NH	CO-NH	α -CH	α -CH	β -CH	β -CH
Lys¹	8.22	125.7	3.89	55.8		
Lys²	8.30	117.5	4.10	55.5	1.94	29.3
Leu³	7.64	112.0	4.13	54.2		
Phe⁴	8.16	116.0	4.04	55.5	2.99 / 3.15	38.9
Lys⁵	8.07	119.4	4.03	55.1		
Lys⁶	7.81	118.8	4.01	56.6	1.78	29.2
Ile⁷	8.09	118.7	3.77	61.4	2.08	34.6
Leu⁸	8.18	119.0	4.01	56.6	1.71	
Lys⁹	7.92	117.8	4.06	55.55		
Lys¹⁰	7.76	119.4	4.08	55.9	1.95	30.1
Leu¹¹	8.04	118.4	4.17	53.0	1.83	


BP389

400 MHz. 20 mM phosphate buffer. pH = 6.5 H₂O/D₂O (90:10)


¹H-NMR




HSQC-TOCSY



HSQC ^1H - ^{15}N



NOESY




BP389

400 MHz. 20 mM phosphate buffer, pH = 6.5 H₂O/D₂O (90:10), containing 30% CF₃CD₂OD


¹H-NMR

** BP389 Estructurat **


1H-RMN with excitation esculpting - 400MHz (Ref. eb9971a9)
(Phosphate buffer 20 mM, pH = 6.5, H₂O/D₂O 90:10 + 30% TFE)




HSQC-TOCSY



HSQC ^1H - ^{15}N




NOESY




BP475

400 MHz. 20 mM phosphate buffer. pH = 6.5 H₂O/D₂O (90:10)


¹H-NMR




HSQC-TOCSY



HSQC ^1H - ^{15}N




NOESY




BP475

400 MHz. 20 mM phosphate buffer, pH = 6.5 H₂O/D₂O (90:10), containing 30% CF₃CD₂OD

¹H-NMR



HSQC-TOCSY



NOESY

